The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Significance of the Phase III FLAURA Study in EGFR+ NSCLC

Joshua Bauml, MD
Published Online: 7:30 PM, Mon September 11, 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the randomized phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non-small cell lung cancer (NSCLC).

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.